News

Adding semaglutide to standard hidradenitis suppurative therapies achieved improvements in quality of life and fewer disease-related flares.

HCPLive spoke to Johnson on how strategies for addressing patient misconceptions about cholesterol management.

The ESS device, leveraging artificial intelligence, may allow for enhanced decision making among nurse practitioners as well as physician assistants evaluating patients for skin cancer.

Nihar Desai, MD, discusses the results of the PROMPT-Lipid trial while on-site at the 2024 Family Heart Global Summit.

Laurence Sperling, MD, discusses his presentation from the 2024 Family Heart Global Summit examining public health efforts for prevention of cardiovascular disease.

Magnetic resonance elastography and transient elastography did not accurately predict high-grade fibrosis on liver biopsy in children with MASLD.

At the Family Heart Summit, Nihar Desai, MD, discussed using EMR alerts to improve lipid therapy for high-risk ASCVD, as shown in the PROMPT-Lipid trial.

These data from the DISCREET study highlight the impact of apremilast on men and women with genital psoriasis.

The FDA has set a PDUFA target action date of May 22, 2025, for roflumilast foam 0.3% for individuals aged ≥12 with scalp and body psoriasis.

Heplisav-B provided a greater vaccine completion rate and higher HBV seroprotection than the conventional 3-dose Recombivax HB in thoracic organ transplant candidates.

A handheld tool improved skin cancer detection in primary care, increasing diagnostic sensitivity to 96.3% compared to 83.9% without the device.

The announcement follows July’s approval of the nasal spray, also known as neffy, for patients with Type 1 allergic reactions such as anaphylaxis.

New research establishes a strong causal link between elevated 25(OH)D levels and a reduced risk of anemia.

Del Rosso reviews several key highlights from his Maui Derm presentation on acne and rosacea updates from 2024.

Subgroup analyses revealed FMT delivered through endoscopy, nasojejunal tube, and rectal enema had a greater impact on clinical response, symptom improvement, and quality of life.

A new case-control study reported a higher prevalence of precocious puberty in children and adolescents with HS compared with controls.

The FDA decision to accept the new drug application for delgocitinib cream is also occurring alongside the drug’s acceptance by the European Commission.

Meta-analysis findings suggest a significant association between MASLD and serious bacterial infection risk.

Obesity and advanced fibrosis were independent predictors of impaired health-related quality of life in people with T2D.

This conference talk was titled Acute & Chronic Spontaneous Urticaria: Diagnostic and Therapeutic Strategies and presented a challenging case series to attendees.

Oral vitamin D improves vitamin D status and quality of life in IBS patients but does not significantly reduce symptom severity, a new study suggests.

Test your knowledge of the phase 3 MAESTRO-NASH trial supporting resmetirom (Rezdiffra)’s FDA accelerated approval for MASH with this quiz.

Del Rosso highlights points from his conference talk on benzoyl peroxide (BPO) use among patients with acne and other updates.

With HepQuant DuO and SHUNT tests, investigators could categorize patients with sclerosing cholangitis into low, moderate, and high disease severity subgroups.

Reau explains the importance of second- and third-line treatment in PBC and the potential implications of no longer having OCA after a negative FDA advisory committee meeting.

Arimoclomol, in combination with miglustat, is approved to treat neurological symptoms associated with NPC in adults and children aged ≥2 years.

As advancements in valvular technology progress, Nguyen highlights the need for long-term data and multidisciplinary collaboration to improve patient outcomes.

This segment of her interview featured a conversation about the biggest takeaways and notable case series presented in Culton’s talk at Maui Derm NP+PA Fall.